Generic selectors
Exact matches only
Search in title
Search in content

Anti-COVID19 Monoclonal Cocktail Prevents Serious Illness In High Risk, Severely Obese Patients at Nanavati Max Hospital

: 12-Jun-2021     : AP     Source : AP

Mumbai, June 12, 2021: Monoclonal Antibody Cocktail, dubbed as a breakthrough treatment for high risk COVID-19 patients helped two severely obese and co-morbid patients recover significantly at Nanavati Max Super Speciality Hospital. Since June 1, the hospital has successfully administered the antibody cocktail in four patients to prevent the probability of serious COVID-19 illness in elderly, high risk patients.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens. The two monoclonal antibodies; Bamlanivimab and Etesevimab are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells, resulting in faster recovery. In February 2021, the U.S. Food and Drugs Administration (FDA) issued an emergency use authorization (EUA) to the antibody cocktail for the treatment of mild to moderate COVID-19 patients. The therapy was introduced in India, in May 2021 to minimise the mutation.
A 58-year-old severely obese and chronic smoker weighing 130kg with a history of severe Obstructive Sleep Apnea Syndrome was the first to receive the antibody cocktail on June 2. “He was a high risk patient with complaints of mild symptoms such as body ache but no hypoxia. Since he had tested positive just two days ago on May 30, we decided to administer the monoclonal cocktail in anticipation of a severe COVID-19 illness,” said Dr Salil Bendre Consultant Pulmonologist, Nanavati Max Super Speciality Hospital. Patient was kept under observation for 48 hours and discharged thereafter. “The patient could’ve suffered a COVID-19 illness due to his existing co-morbidity. But two weeks on, he is stable and asymptomatic,” Dr Bendre added.

The antibody cocktail is proving to be beneficial for a bedridden 50-year-old woman (125kg) with history of poliomyelitis, hypertension and borderline diabetes. Dr Girish Parmar, Senior Consultant, Endocrinology and Diabetology, Nanavati Max Super Speciality Hospital, who’s been treating the woman said that she visited the hospital on 7th day of COVID-19 infection. “Patient had mild symptoms such as cough and fever. Since she was a high-risk patient, within the initial window of disease advancement, we administered the Monoclonal Cocktail on June 9. She is currently asymptotic and shows signs of speedy recovery,” said Dr Parmar.

The other two patients who have received the antibody cocktail include a 50-year-old woman with uncontrolled diabetes and cardiac issues and a 57-year-old man with hypertension, who’s fever didn’t subside for seven days. Both patients had mild symptoms but despite the comorbidities, showed signs of early recovery due to the monoclonal antibodies.

Talking about the antibody cocktail therapy, Ms. Mangla Dembi, Senior Vice President and Head Operations at Nanavati Max Super Speciality Hospital said, “We are proud of our seasoned team of medical experts who prevented probable poor outcome in high risk COVID-19 patients using such effective drug cocktail. As a part of Max Healthcare group, we will continue to discover newer frontiers of advanced clinical protocols for the well-being of our patients.”

 

Categories: Health Business | Comments
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments